Skip to main content
. 2016 Jan 7;7(1):45–50. doi: 10.15171/jlms.2016.10

Table 3 . Changes in Mean VAS in Groups in Each Muscle During the Whole Treatment Phase and Follow-up .

1st Visit 2nd Visit 3rd Visit 4th Visit 5th Visit 6th Visit 7th Visit 8th Visit 9th Visit 10th Visit 11th Visit 12th Visit Follow
Masseter
Mean (laser group) 7.61 ± 1.04 5.69 ± 1.75 4.69±2.01 4.15 ± 1.86 3.15 ± 1.86 2.84±1.77 2.00 ± 1.82 1.46 ± 1.50 1.07 ± 1.25 0.69 ± 0.94 0.53 ± 0.87 0.30 ± 0.63 0.30 ± 0.63
Mean (naproxen group) 7.05 ± 1.51 6.70 ± 1.57 6.29±1.57 5.88 ± 1.53 5.70 ± 1.53 5.52±1.69 5.52 ± 1.66 5.70 ± 1.53 5.70 ± 1.53 5.76 ± 1.60 5.76 ± 1.56 5.82 ± 1.59
P (2 tailed) 0.268 0.107 0.021 0.009 000 000 000 000 000 000 000 000 000
Temporalis
Mean (laser group) 7.61 ± 1.04 5.69 ± 1.75 4.69±2.01 4.15 ± 1.86 3.15 ± 1.86 2.84±1.77 2.00 ± 1.82 1.46 ± 1.50 1.07 ± 1.25 0.69 ± 0.94 0.53 ± 0.87 0.30 ± 0.63 0.30 ± 0.63
Mean (naproxen group) 7.05±1.51 6.70 ± 1.57 6.29±1.57 5.88 ± 1.53 5.70 ± 1.53 5.52±1.69 5.52 ± 1.66 5.70 ± 1.53 5.70 ± 1.53 5.76 ± 1.60 5.76 ± 1.56 5.82 ± 1.59
P (2 tailed) 0.268 0.107 0.021 0.009 000 000 000 000 000 000 000 000 000
Medial Pterygoid
Mean (laser group) 7.30 ± 0.39 6.69 ± 0.54 5.33±0.46 4.30 ± 0.51 3.30 ± 0.47 2.38±0.48 1.38 ± 0.43 0.84 ± 0.38 0.69 ± 0.32 0.46 ± 0.21 0.23 ± 0.12 0.23 ± 0.12 0.23 ± 0.12
Mean (naproxen group) 5.9 ± 0.46 5.2 ± 0.46 5.08±0.46 4.75 ± 0.46 4.50 ± 0.50 4.25±0.50 4.33 ± 0.48 4.50 ± 0.46 4.58 ± 0.46 4.58 ± 0.49 4.75 ± 0.49 4.91 ± 0.48
P (2 tailed) 0.58 0.56 0.53 0.53 0.09 0.015 000 000 000 000 000 000 000
Lateral Ptreygoid
Mean (laser group) 6.33 ± 0.69 5.75 ± 0.59 4.50±0.51 3.58 ± 0.49 2.58 ± 0.59 2.41±0.59 1.41±0.43 0.75 ± 0.30 0.83 ± 0.32 0.41± 0.33±0.19 0.33±0.18 0.50±0.19
Mean (naproxen group) 5.70 ± 0.33 5.20 ± 0.32 4.90±0.31 4.80 ± 0.32 4.70 ± 0.33 4.30±0.39 4.20±0.32 4.40 ± 0.304 4.50 ± 0.37 4.70±0.36 4.90±0.37 4.90±0.37
P (2 tailed) 0.406 0.451 0.535 0.065 0.008 0.020 000 000 000 000 000 000 000